- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gilead Sciences Inc (GILD)
Gilead Sciences Inc stock price live, this page displays NASDAQ GILD stock exchange data. View the GILD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Gilead Sciences Inc real time stock price chart below.
What Is the Gilead Sciences Inc Stock Price Today?
The Gilead Sciences Inc stock price today is 118.30.
What Is the Stock Symbol for Gilead Sciences Inc?
The stock symbol for Gilead Sciences Inc is ""GILD.""
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the NASDAQ stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead Sciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GILD quote. (ISIN: US3755581036)
What Is the Gilead Sciences Inc Stock Price Today?
The Gilead Sciences Inc stock price today is 118.30.
What Is the Stock Symbol for Gilead Sciences Inc?
The stock symbol for Gilead Sciences Inc is ""GILD.""
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the NASDAQ stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead Sciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GILD quote. (ISIN: US3755581036)
Fair Value
An estimate of a Gilead's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
117.07
119.07
52 wk Range
85.60
121.83
GILD Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
Earnings results expected in 14 days
1/2
Fair Value
An estimate of a Gilead's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
117.07119.07
52 wk Range
85.60121.83
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.67%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.67%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GILD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Gilead's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
126.31
Upside
+6.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Gilead Sciences Inc Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences Inc SWOT Analysis
HIV Market Dynamics | Explore Gilead's strategies to maintain dominance in HIV therapeutics amid challenges like formulary exclusions and potential government funding cuts |
Oncology Ambitions | Discover how Gilead's expanding oncology portfolio, led by Trodelvy and Cell therapies, is poised to drive future growth and valuation |
Financial Health | Delve into Gilead's robust financial position, with a market cap of $140.17B and strong EBITDA, supporting its ambitious commercial initiatives |
Analyst Outlook | Learn about Gilead's price targets, ranging from $115 to $130, reflecting diverse views on the company's growth potential and market positioning |
Gilead Sciences Inc Earnings Call Summary for Q1/2025
- Q1 EPS beat expectations at $1.81, but revenue fell short at $6.67 billion; stock dropped 3.4% after hours
- HIV product sales grew, with Biktarvy up 7% to $3.1 billion; cell therapy faced competitive pressures
- Full-year product sales guidance: $28.2-$28.6 billion; flat HIV sales expected due to Medicare Part D redesign
- Preparing for launches including lenacapavir for PrEP; R&D and SG&A expenses decreased, showing cost management
- Strong fundamentals with robust free cash flow yield; dividend raised for 10 consecutive years, currently yielding 2.97%
Last Updated: 24/04/2025, 22:44
Read Full TranscriptCompare GILD to Peers and Sector
Metrics to compare | GILD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGILDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 23.3x | −2.9x | −0.7x | |
PEG Ratio | 0.05 | 0.00 | 0.00 | |
Price/Book | 7.5x | 1.7x | 2.6x | |
Price / LTM Sales | 5.1x | 37.7x | 3.3x | |
Upside (Analyst Target) | 8.0% | 50.3% | 37.1% | |
Fair Value Upside | Unlock | −1.1% | 4.7% | Unlock |
Analyst Ratings
20 Buy
8 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 126.31
(+6.77% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
2.01 / 1.96
Revenue / Forecast
7.10B / 6.97B
People Also Watch
FAQ
What Stock Exchange Does Gilead Trade On?
Gilead is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Gilead?
The stock symbol for Gilead is "GILD."
What Is the Gilead Market Cap?
As of today, Gilead market cap is 146.79B.
What Is Gilead's Earnings Per Share (TTM)?
The Gilead EPS (TTM) is 5.01.
When Is the Next Gilead Earnings Date?
Gilead will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is GILD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Gilead Stock Split?
Gilead has split 5 times.
How Many Employees Does Gilead Have?
Gilead has 17600 employees.
What is the current trading status of Gilead (GILD)?
As of 16 Oct 2025, Gilead (GILD) is trading at a price of 118.30, with a previous close of 118.48. The stock has fluctuated within a day range of 117.07 to 119.07, while its 52-week range spans from 85.60 to 121.83.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.